Scientia Pharmaceutica (May 2021)

Evaluation of Anticonvulsant Activity of Dual COX-2/5-LOX Inhibitor Darbufelon and Its Novel Analogues

  • Mariia Mishchenko,
  • Sergiy Shtrygol’,
  • Andrii Lozynskyi,
  • Semen Khomyak,
  • Volodymyr Novikov,
  • Olexandr Karpenko,
  • Serhii Holota,
  • Roman Lesyk

DOI
https://doi.org/10.3390/scipharm89020022
Journal volume & issue
Vol. 89, no. 2
p. 22

Abstract

Read online

Neuroinflammation is an integral part of epilepsy pathogenesis and other convulsive conditions, and non-steroidal anti-inflammatory drugs (NSAIDs) present a potent tool for the contemporary search and design of novel anticonvulsants. In the present paper, evaluation of the anticonvulsant activity of the potential NSAID dual COX-2/5-LOX inhibitor darbufelone methanesulfonate using an scPTZ model in mice in dose 100 mg/kg is reported. Darbufelone possesses anticonvulsant properties in the scPTZ model and presents interest for in-depth studies as a possible anticonvulsant multi-target agent with anti-inflammatory activity. The series of 4-thiazolidinone derivatives have been synthesized following the analogue-based drug design and hybrid-pharmacophore approach using a darbufelone matrix. The synthesized derivatives showed a significant protection level for animals in the scPTZ model and are promising compounds for the design of potential anticonvulsants with satisfactory drug-like parameters.

Keywords